DLA Piper advised the underwriters on a US$50 million offering of common stock for Jasper Therapeutics

DLA Piper advised TD Cowen, Evercore and RBC on a US$50 million underwritten offering of common stock for Jasper Therapeutics, a clinical-stage biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases, such as chronic spontaneous urticaria (CSU) and lower to intermediate risk myelodysplastic syndromes (MDS), as well as novel stem cell transplant conditioning regimes. TD Cowen and Evercore served as joint book-running managers, and RBC served as lead manager.

“Congratulations to our clients TD Cowen, Evercore and RBC, as well as Jasper on the successful closing of this offering,” said Stephen Alicanti, the DLA Piper partner who led the deal team. “On behalf of our team, it was a pleasure to work on this deal and have an opportunity to demonstrate our extensive life sciences and capital markets capabilities.”

In addition to Alicanti (New York), the DLA Piper team included associates Gina Lee and Kim McKenzie (both in Raleigh) and Sasha Grynszpan (New York).

DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients’ needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.

DLA Piper’s global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investment grade and high-yield debt securities.